AstraZeneca's experimental gout drug shows promise in 3 trials

08/13/2014 | Reuters

AstraZeneca said its experimental gout drug lesinurad, in combination with existing drugs, performed well in three Phase III trials. The drug, however, caused a higher amount of side effects, particularly at higher doses. The firm said it is preparing to submit for regulatory review a 200-milligram dose of the drug in combination therapy.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN